Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Corrigendum to "Efficacy and potential mechanisms of alkaloids in animal models for pulmonary fibrosis: a study integrating preclinical systematic review and meta-analysis, network pharmacology and molecular docking" [Int. Immunopharmacol. 184C (2026) 116908].

International immunopharmacology·2026
Same author

Efficacy and potential mechanisms of alkaloids in animal models for pulmonary fibrosis: a study integrating preclinical systematic review and meta-analysis, network pharmacology and molecular docking.

International immunopharmacology·2026
Same author

A meta-analysis of the clinical significance of red blood cell distribution width in chronic obstructive pulmonary disease.

Biomarkers in medicine·2026
Same author

Natural products targeting the immune-metabolic regulatory network in pulmonary hypertension: mechanisms, classification, and therapeutic prospects.

Frontiers in pharmacology·2026
Same author

Life's Essential 8 and cardiovascular health: Protective effects on chronic respiratory diseases.

International journal of cardiology. Cardiovascular risk and prevention·2026
Same author

Transcriptome-Wide N7-Methylguanosine (m7G) Map Profiling Reveals the Regulatory Role of m7G in Atherosclerosis.

FASEB journal : official publication of the Federation of American Societies for Experimental Biology·2025
Same journal

Evidence-Based Clinical Recommendations for the Appropriate Use of Diagnostic Tests in Pediatric Allergology: Focus on Asthma, Rhinoconjunctivitis, and Keratoconjunctivitis Vernal.

Journal of clinical medicine·2026
Same journal

Surgical and Transcatheter Approach of a Failed Mitral Valve Repair: A Comprehensive Review on Selecting the Most Suitable Approach.

Journal of clinical medicine·2026
Same journal

Hybrid Metaheuristic Feature Selection for Breast Cancer Detection in Digital Mammography: A Feasibility Study with Nested Validation, Benchmarking, and External Stress Testing.

Journal of clinical medicine·2026
Same journal

Identity Transformation and the Role of Accountability in Recovery from Problematic Pornography Use: A Phenomenological-Hermeneutical Study.

Journal of clinical medicine·2026
Same journal

Does Early Surgical Treatment in Degenerative Cervical Myelopathy Have a Favorable Clinical Outcome and Impact on Quality of Life?

Journal of clinical medicine·2026
Same journal

Shear Wave Elastography in Musculoskeletal Imaging: A Narrative Review.

Journal of clinical medicine·2026
See all related articles

Related Experiment Video

Updated: Jun 28, 2026

Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma
04:09

Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma

Published on: October 10, 2018

8.3K

Predicting Hepatotoxicity Associated with Low-Dose Methotrexate Using Machine Learning.

Qiaozhi Hu1, Hualing Wang2, Ting Xu1

  • 1Department of Pharmacy, West China Hospital, Sichuan University, Chengdu 610041, China.

Journal of Clinical Medicine
|February 25, 2023
PubMed
Summary
This summary is machine-generated.

This study developed a machine learning model to predict liver damage from low-dose methotrexate. Key risk factors identified include body mass index, age, number of drugs, and comorbidities, improving patient safety.

Keywords:
hepatotoxicitylow-dose methotrexatemachine learningprediction modelrisk factor

More Related Videos

Machine Learning Algorithms for Early Detection of Bone Metastases in an Experimental Rat Model
07:15

Machine Learning Algorithms for Early Detection of Bone Metastases in an Experimental Rat Model

Published on: August 16, 2020

6.9K
Comparison of Predictive Performance of Three Lymph Node Staging Systems in Colorectal Signet Ring Cell Carcinoma Based on Machine Learning Model
07:13

Comparison of Predictive Performance of Three Lymph Node Staging Systems in Colorectal Signet Ring Cell Carcinoma Based on Machine Learning Model

Published on: April 18, 2025

168

Related Experiment Videos

Last Updated: Jun 28, 2026

Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma
04:09

Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma

Published on: October 10, 2018

8.3K
Machine Learning Algorithms for Early Detection of Bone Metastases in an Experimental Rat Model
07:15

Machine Learning Algorithms for Early Detection of Bone Metastases in an Experimental Rat Model

Published on: August 16, 2020

6.9K
Comparison of Predictive Performance of Three Lymph Node Staging Systems in Colorectal Signet Ring Cell Carcinoma Based on Machine Learning Model
07:13

Comparison of Predictive Performance of Three Lymph Node Staging Systems in Colorectal Signet Ring Cell Carcinoma Based on Machine Learning Model

Published on: April 18, 2025

168

Area of Science:

  • Pharmacology and Toxicology
  • Medical Informatics
  • Machine Learning in Medicine

Background:

  • Low-dose methotrexate is used for immune disorders, but hepatotoxicity is a concern.
  • Accurate prediction of liver toxicity is crucial for safe treatment decisions.

Purpose of the Study:

  • To develop and validate a machine learning model for predicting methotrexate-induced hepatotoxicity.
  • To identify significant risk factors associated with liver damage in patients receiving low-dose methotrexate.

Main Methods:

  • Retrospective study of 782 patients with immune system disorders treated with low-dose methotrexate.
  • Eight machine learning algorithms (XGBoost, AdaBoost, CatBoost, GBDT, LightGBM, TPOT, RF, ANN) were evaluated.
  • The Random Forest model demonstrated the best predictive performance.

Main Results:

  • Hepatotoxicity was observed in 35.68% of patients.
  • The Random Forest model achieved an AUC of 0.97, with 64.33% accuracy.
  • Top risk factors identified were body mass index (0.237), age (0.198), number of drugs (0.151), and comorbidities (0.144).

Conclusions:

  • A machine learning-based predictive model for methotrexate-related hepatotoxicity was successfully established.
  • The model and identified risk factors can enhance medication safety for patients on methotrexate.
  • This approach offers a valuable tool for clinical practice in managing methotrexate therapy.